1879 results about "Immunotherapy" patented technology

The invention discloses an intestinal cancer immune response graph neural network prediction method, a medium and equipment, and the method comprises the steps: collecting pathological image information, immunodetection information and basic clinical information, extracting a tissue space distribution characteristic spectrum through a deep convolutional network, and constructing a graph neural network model in combination with an immunomarker expression characteristic matrix; spatial interaction characteristics of a tumor microenvironment are modeled by adopting a graph attention mechanism, finally a treatment response probability, an optimal treatment opportunity and an adverse reaction risk are predicted through a multi-task learning framework, and a clinical decision report containing a prediction response curve, a risk early warning threshold and a treatment time window suggestion is output. According to the method, through multi-modal data fusion and spatial interaction modeling, accurate prediction of intestinal cancer immunotherapy response is realized, and a more comprehensive reference basis is provided for clinical decision making.

The invention discloses a renal clear cell carcinoma prognosis prediction method based on multi-mode MRI (Magnetic Resonance Imaging) image and digital pathological omics fusion. The method comprises the following steps: S1, collecting a training data set based on an MR image and a pathological image; s2, feature extraction of MR radiomics; s3, deep learning feature extraction of the pathological image; s4, an MR-pathological feature fusion module; and S5, deploying the network. According to the method, depth features with prognosis information are obtained from two scales of pre-treatment images and post-operation pathology, effective features are extracted by adopting image omics and a convolutional neural network mode according to data characteristics of MR images and pathology images, and depth fusion of the two types of features is completed in a hidden space through a multi-task guiding mode, so that the accuracy of the MR image and the pathology image is improved. A precise prognosis model with multi-scale information is provided, and the method has a relatively strong clinical application prospect and is of great significance for realizing precise immunotherapy and improving prognosis of a patient.

Methods, apparatus, systems, and articles of manufacture are disclosed for generation and application of models for therapeutic prediction and processing. A balance of precision and recall can be applied to at least one of a toxicity-related model or an efficacy-related model to configure immunotherapy treatment of a patient and / or cohort of patients. Model output can be evaluated differently depending on a determine patient selection criterion to trigger different actions.

The invention discloses preparation of a targeting LYPD3 antibody and application of the targeting LYPD3 antibody in tumor immunotherapy. The antibody or antigen binding fragment thereof comprises a heavy chain variable region having CDR-H1, CDR-H2 and CDR-H3 and a light chain variable region having CDR-L1, CDR-L2 and CDR-L3 wherein CDR-H1, CDR-H2 and CDR-H3 comprise the amino acid sequences of SEQ ID NO: 3, SEQ ID NO: 4 and SEQ ID NO: 5, respectively, and CDR-L1, CDR-L2 and CDR-L3 comprise the amino acid sequences of SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, respectively.

Presented herein are systems, methods, and non-transient computer readable media for determining predicted response scores of subjects. A computing system may identify a first feature set for a first subject to be administered with immunotherapy to address a condition. The first feature set may include one or more of: (i) a first radiological feature identified in a tomogram of a section associated with the condition in the first subject, (ii) a first immunohistochemistry (IHC) feature derived from an image of a sample associated with the first subject, and (iii) a first genomic feature obtained from gene sequencing of the first subject for genes associated with the condition. The computing system may apply the first feature set to a model. The computing system may determine, from applying the first feature set to the model, a predicted score identifying a response to the immunotherapy to be administered to the first subject.

The invention belongs to the technical field of genetic engineering and biological medicine, and particularly discloses a cascade response type nano-particle with a microenvironment remodeling function and a preparation method and application of the cascade response type nano-particle. The nanoparticle provided by the invention adopts a bionic hybrid membrane engineering strategy: an inner core is formed by loading an exosome inhibitor on a nano material, and the surface is covalently coupled with M2 type macrophage specific targeting peptide; the outer layer coats a macrophage membrane and active oxygen response type liposome composite membrane layer through a co-extrusion technology, and is loaded with a TLR agonist. Animal experiments show that after being injected through caudal vein, the nano-particles are enriched at a tumor site in a targeted manner through homing receptors such as membrane surface integrin alpha4beta1 and the like, and outer membrane cracking is triggered in a high-ROS tumor microenvironment, so that space-time controlled release of a TLR agonist and targeted phagocytosis of an exosome inhibitor by macrophages guided by a targeted peptide are realized. The anti-tumor synergistic effect is achieved through multiple regulation and control mechanisms, and an effective treatment strategy is provided for tumor immunotherapy.

The invention belongs to the cross technical field of nanomedicine, tumor treatment and immunotherapy, and particularly provides tumor mitochondria-targeted copper death selective induction nanoparticles, which are prepared by the following preparation method: S1, specifically coupling TPY and MHI through condensation reaction to obtain MTPY; s2, MTPY and copper ions are subjected to complexation, and an MTPY-Cu complex is obtained; and S3, the MTPY-Cu complex and albumin are subjected to self-assembly, and the MTPY-Cu-coated Alb nanoparticles are formed. The dosage of copper is only 1 / 1000 of that of free Cu < 2 + >, and equivalent immune regulation and killing effects can be achieved; primary tumors and distant tumor focuses can be inhibited, and lung metastasis is reduced; immune memory can be induced, and relapse can be prevented; the traditional Chinese medicine composition is combined with cis-platinum to remarkably enhance the curative effect and reverse the induced immunosuppression; the invention has the advantages of high biological safety and no obvious liver and kidney toxicity or hemolytic reaction.

Described herein are methods and systems of performing immunotherapy on a subject and / or determining if a subject will be responsive to ablation immunotherapy.

The invention provides a coordination nano assembly of chiral cyclopeptide and manganese ions as well as a preparation method and application of the coordination nano assembly. According to the method, a manganese superoxide dismutase protein structural domain and a unique tumor microenvironment of melanoma high tyrosinase are combined, and polypeptide sequences L-YD-hL-DD-h, L-YL-HL-DL-H and D-yD-hD-dD-h with different chirality are designed for the first time; the chirality of the polypeptide is regulated and controlled, the in-vivo circulation stability and the cell entry efficiency of the nano assembly are improved, the coordination self-assembly of manganese and different chiral cyclopeptides is realized, and the in-situ oxidation of an in-vivo tumor microenvironment is simulated for photo-thermal therapy and cell membrane coating. The method disclosed by the invention is simple, mild in experimental condition and easy to operate, the prepared cell membrane coated nano assembly not only has long circulation stability and high cell entry efficiency, but also can realize mild photo-thermal therapy through in-situ oxidation, releases manganese ions to activate a CGAS-STING pathway for immunotherapy of tumors, and has a wide application prospect. The potential application value is realized in the field of combined treatment of tumors.

The invention provides an AS01 derivative adjuvant, a preparation method thereof and application of the AS01 derivative adjuvant in preparation of vaccines or anti-tumor drugs, and belongs to the technical field of biological drugs or products. The AS01 derivative adjuvant is prepared from the following components in parts by mass: 0.5 to 1.0 part of cholesterol, 2.0 to 4.0 parts of dioleoyl lecithin and at least one of the following components in parts by mass: 0.1 to 0.2 part of monophosphoryl lipid A, 0.1 to 0.2 part of QS-21, 0.36 to 0.72 part of 3M-052, 0.4 to 0.8 part of muramyl dipeptide and 0.2 to 0.4 part of oligodeoxynucleotide. According to the AS01 derived adjuvant, a novel synergistic adjuvant system is developed by integrating various immunomodulators, so that the immunogenicity of a vaccine is enhanced. The HPV vaccine is prepared on the basis of the AS01 derived adjuvant, so that the immunogenicity can be enhanced, and good anti-tumor activity can be achieved. Therefore, the invention provides a new strategy for immunotherapy of HPV-related tumors.

The invention belongs to the technical field of immunotherapy, and particularly relates to a monkey pox virus antigen epitope peptide and application thereof. The invention aims to solve the technical problem that at present, a T cell antigen epitope peptide for universal vaccines of monkey pox viruses is not developed in the field of monkey pox viruses. According to the technical scheme of the invention, the amino acid sequence of the monkey pox virus antigen epitope peptide is shown as SEQ ID No.2. The antigen epitope peptide provided by the invention has very strong immunogenicity, and can induce antigen-specific CD8 + T cells; the antibody can be directly loaded to antigen presenting cells, can activate T cells and effectively induce T cell immunity, and can be used for research and development and preparation of universal vaccines for monkey pox viruses, research and development of drugs and clinical treatment.

The invention discloses a tumor immunotherapy curative effect prediction method and system based on multi-modal data, and the method comprises the steps: firstly, obtaining the multi-source tumor data of a patient, including pathological image data, medical image data, genome and molecular data, and clinical and demographic indexes; secondly, processing the multi-source tumor data to form a unified data set; thirdly, aiming at different modal data, adopting a corresponding feature extraction sub-network to extract each modal depth feature; then, a cross-modal attention mechanism is adopted to realize feature dynamic weighting and deep fusion, and unified multi-modal fusion representation is obtained; then, constructing a prediction model, and outputting an immunotherapy benefited population classification identification result, RECIST curative effect multi-classification prediction and survival prediction; and finally, generating a visual result and a feature contribution degree ranking of a prediction basis, and forming a clinical auxiliary decision report. According to the method, the prediction accuracy and stability can be remarkably improved, and meanwhile, the method has result interpretability and clinical application value.

The invention belongs to the technical field of immunotherapy, and particularly relates to a method for improving NK cell functions by targeted inhibition of lactylation. The invention provides a method for improving functions of NK cells by targeted inhibition of lactylation, NK cell lactic acid transporters or modification enzymes in inhibition of the lactylation process are targeted, the modification enzymes are NK cell lactylation modification enzymes Writer or lactic acid coenzyme A synthetase, NK92MI lactylation modification is blocked, so that function depletion of the NK cells is reversed, and the NK cell function is improved. The function of the NK cell can be partially reversed by inhibiting the lactic acid modification, and the expression level of effector molecules of the NK92MI cell can be recovered.

The invention discloses a monoclonal antibody targeting all CD45 subtypes and application of the monoclonal antibody, and belongs to the field of monoclonal antibody preparation. The hybridoma cell strain capable of stably secreting all anti-human CD45 subtype antibodies is successfully obtained by stably expressing short and long molecular subtypes of human CD45 extracellular regions in L929 mouse fibroblasts, immunizing BALB / c mice with L929 cells expressing the two molecular subtypes of human CD45, and fusing splenocytes with SP20 myeloma cells after the serum titer reaches the standard. And the monoclonal antibody targeting all subtypes of CD45 is obtained. The monoclonal antibody provided by the invention shows a high-affinity binding characteristic with all human CD45 molecular subtypes, has important application value in the aspect of human CD45 molecular detection, and can be used as a therapeutic antibody in the fields of tumor immunotherapy, autoimmune disease treatment, transplant rejection resistance and the like.

The invention relates to a plasma biomarker for predicting the curative effect of non-small cell lung cancer immunotherapy and application of the plasma biomarker. The biomarker for predicting the curative effect of the non-small cell lung cancer immunotherapy, disclosed by the invention, comprises phosphoglycerate kinase 1 (PGK1), fibronectin 1 (FN1), chromogranin A (CHGA), elastin (ELN), heterogeneous ribonucleoprotein H3 (HNRNPH3) and an Aly / REF output factor (ALYREF). The plasma biomarkers for predicting the non-small cell lung cancer immunotherapy curative effect can be detected by adopting a mass spectrum method, and the non-small cell lung cancer immunotherapy curative effect of a patient is judged by the markers.

The present invention provides an enhanced NK cell, its preparation method and application, belonging to the field of biomedical technology. The present invention uses a compound of quercetin, paclitaxel and resveratrol as a culture medium induction additive to pre-treat NK cells, successfully enhancing the killing toxicity of NK cells against human lung cancer cells and effectively inhibiting tumor growth, opening up a new way for the treatment of lung cancer and having important research value and potential clinical application prospects in the field of tumor immunotherapy.

The invention belongs to the field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition for treating triple negative breast cancer and application thereof. The traditional Chinese medicine composition is prepared from the following main active ingredients in parts by mass: 20 to 40 parts of radix astragali seu hedysari, 10 to 20 parts of rhizoma curcumae, 10 to 20 parts of herba hedyotidis diffusae, 5 to 15 parts of fructus aurantii immaturus, 5 to 15 parts of radix bupleuri, 5 to 15 parts of radix paeoniae alba and 5 to 15 parts of liquorice root. Animal experiments show that the traditional Chinese medicine composition can significantly inhibit tumor growth and pulmonary metastasis of triple-negative breast cancer tumor-bearing mice, increase the proportion of CD8 + T lymphocytes in blood, reduce the proportion of MDSCs, significantly down-regulate the expression of pro-inflammatory cytokines such as IL-6, IL-1alpha, CXCL1 and GM-CSF in serum, and cooperate with PD-L1 immunotherapy to achieve a synergistic effect. And the whole blood and liver and kidney function indexes are in a normal range. Therefore, the traditional Chinese medicine composition disclosed by the invention can be used for effectively inhibiting the tumor growth and pulmonary metastasis of the triple negative breast cancer, remodeling the immune state of an organism and reducing the release of proinflammatory factors, and is safe, reliable, free of obvious liver and kidney toxicity and blood toxicity and small in side effect.

The invention relates to a gadolinium-doped carbon dot complex based on liver cancer cell membrane coating and a preparation method of the gadolinium-doped carbon dot complex. The gadolinium-doped carbon dot complex is prepared on the basis of gadolinium-doped carbon dots Gd-CDs which are prepared from indocyanine green, citric acid, polyethylene glycol and gadolinic acid through a one-step microwave thermal method and have fluorescence-magnetic resonance bimodal imaging capacity. The Gd-CDs complex Gd-CDs coated HCM is placed in a cell membrane suspension extracted from human hepatoma carcinoma cells HepG2, and the Gd-CDs complex Gd-CDs coated HCM which is uniform in particle size and has the capacity of photothermal and immunotherapy of hepatocellular carcinoma is obtained through extrusion construction of a liposome extruder. The Gd-CDs (at) HCM complex constructed by the invention not only has good bimodal imaging ability, but also has a specific inhibition effect on liver tumor cells, can be applied to preparation of drugs for inhibiting the growth of the liver tumor cells, and realizes a good treatment effect on liver cancer at a nanometer level.

The invention discloses an anti-CLDN6 nano antibody and related application thereof, and relates to the field of antibodies. The invention provides an anti-CLDN6 nano antibody, which comprises HCDR1, HCDR2 and HCDR3 in a heavy chain variable region of which the amino acid sequence is as shown in SEQ ID NO: 4, the nano antibody has excellent antigen binding activity, high specificity and good affinity, has relatively strong killing activity on cells with high expression of CLDN6, and can be used for preparing anti-CLDN6 drugs. The requirements of CLDN6 positive tumor immunotherapy on efficient, specific and high-penetrability antibody molecules are met, and a new strategy and means are provided for tumor therapy.

The invention provides an anti-NKG2A antibody or an antigen binding fragment thereof and application of the anti-NKG2A antibody or the antigen binding fragment thereof. The antibody or the antigen binding fragment thereof comprises VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2 and VL-CDR3. The antibody or the antigen binding fragment thereof has the potential of treating tumors, and provides a choice for clinical tumor immunotherapy medication.

The invention relates to the field of immunology, and particularly discloses a TCR combination and application thereof, the TCR combination is used for recognizing HBV antigen epitopes, the TCR combination comprises a plurality of separated TCRs, the plurality of separated TCRs form two TCR groups, and the two TCR groups comprise a first TCR group and a second TCR group; wherein the first TCR group specifically recognizes a first antigen epitope, and the amino acid sequence of the first antigen epitope is as shown in SEQ ID NO: 1; the first TCR group specifically recognizes a first antigen epitope, the second TCR group specifically recognizes a second antigen epitope, the amino acid sequence of the second antigen epitope is shown as SEQ ID NO: 2, the second antigen epitope respectively and correspondingly recognizes different antigen epitopes, the hepatitis B virus specific TCR and the epitope thereof are screened out, and an important means can be provided for treatment of TCR-T immune cells infected by hepatitis B virus.

The invention belongs to the technical field of biological medicines, and relates to application of Ackermann muciniphile or its external vesicles in preparation of a drug for treating schistosomiasis. The anti-infection immunity of a host is enhanced by adjusting intestinal flora balance (recovering diversity and composition) and improving immune response (adjusting macrophage, CD8 + T cell recruitment and Th1 / Th2 balance); meanwhile, the intestinal barrier function is improved, and pathogen invasion and inflammation are reduced; hepatic granuloma and hepatic fibrosis caused by schistosome infection are obviously relieved, and the liver function is improved; the key effect of the MIF gene in immunoregulation is disclosed, and a new direction is provided for schistosomiasis immunotherapy. Besides, the probiotics are high in treatment safety and free of obvious side effects, can be combined with chemotherapy to enhance the curative effect and reduce the side effects and drug resistance of chemical drugs, provides a lasting and comprehensive adjuvant therapy scheme for the schistosomiasis, and has important clinical application potential.

The invention belongs to the technical field of preparation of polypeptides, and particularly relates to a self-assembled polypeptide capable of responding to alkaline phosphatase and degrading Neuropilin-1 as well as a preparation method and application of the self-assembled polypeptide. The self-assembled polypeptide (formula I) provided by the invention has a self-assembly starting unit 'GNNQQNY (SEQ ID NO: 1)', can be self-assembled in vitro, and can form nanofibers after responding to alkaline phosphatase, so that not only can the critical self-assembly concentration of the polypeptide be reduced, but also the binding capacity with target protein can be improved. The material can degrade NRP1 on the surfaces of tumor cells and Treg cells, and has huge potential in promoting immunotherapy of tumors.

The invention discloses a CAR-T treatment response intelligent prediction system based on medical images, and relates to the field of medical image analysis and tumor immunotherapy, and the system comprises a data integration module, a multi-modal feature extraction module, a prediction model construction module, a model optimization module, a clinical analysis module and an adverse reaction risk early warning module. The system integrates PET-CT, MRI, ultrasound and other multi-mode medical image data, and extracts the form, texture and metabolic characteristics of the tumor; constructing a treatment response prediction model by adopting a three-dimensional convolutional neural network; innovatively applying a differential geometry theory, constructing a medical image manifold structure and generating a tumor adversarial sample maintaining topological characteristics, and executing an adaptive optimization strategy by using a Riemannian metric space; accurate prediction of CAR-T treatment response of a lymphoma patient is realized, and adverse reaction risk early warning is carried out through brain and visceral organ image analysis.

The invention relates to a biomarker combination for clinical benefit of non-small cell lung cancer immunotherapy and application of the biomarker combination. The biomarker for predicting the clinical benefit of the non-small cell lung cancer immunotherapy comprises an immune globulin kappa light chain variable region 1-27 (IGKV1-27), a human leukocyte antigen H (HLA-H), an S100 calcium binding protein A8 (S100A8), a chromogranin A (CHGA), an elastin (ELN) and a nephronectin (NPNT). The biomarkers for predicting the clinical benefit of the immunotherapy of the non-small cell lung cancer can be detected, and the clinical benefit effect of the immunotherapy of the non-small cell lung cancer of a patient is judged by the markers.

The invention relates to the technical field of medical artificial intelligence, and discloses a non-small cell lung cancer immunotherapy risk assessment method and system and a storage medium, and the method comprises the steps: constructing an optimal strategy tree model capable of dividing a patient into a plurality of subgroups based on a historical patient data set, and determining an initial optimal treatment strategy for each subgroup; determining a subgroup to which a new patient belongs and an initial treatment strategy thereof according to the model; in the treatment process, the deviation degree between the individual response trajectory of the patient and the average response trajectory of the subgroup to which the individual response trajectory belongs is calculated; and when the deviation degree exceeds a preset threshold value of the subgroup, triggering an adaptive adjustment mechanism, and outputting an updated treatment suggestion. By establishing a dynamic monitoring and closed-loop feedback mechanism based on the subgroup benchmark, the technical problem that an existing scheme is difficult to carry out prospective identification and dynamic intervention on individualized risks is solved, so that the accuracy, safety and individualized level of non-small cell lung cancer immunotherapy are improved.

Methods for selecting a cancer patient for immunotherapy comprise establishing a total passenger gene mutation burden from a tumor of a cancer patient, generating a background distribution for the mutational burden of the tumor, normalizing the total passenger gene mutation burden against the background distribution, and categorizing the cancer patient as an immunotherapy responder when the total passenger gene mutation burden is greater than the mean of the background distribution. When the cancer patient is an immunotherapy responder, the patient may be administered an immunotherapy regimen that comprises activation / inhibition of T cell receptors that promote T cell activation and / or prolong immune cytolytic activities.

The invention relates to the field of image processors and biological medicines, and discloses an NK cell activity rapid detection method based on image processing. The method comprises the following steps: acquiring an unmarked time sequence phase image sequence of an NK cell and target cell co-culture system; performing cell instance segmentation to track individual cells; extracting a morphological dynamic characteristic parameter set of the target cell, wherein the morphological dynamic characteristic parameter set comprises a volume change rate, a phase gradient entropy, a cytoplasm phase fluctuation frequency and a nuclear region phase mean value; inputting the parameters into a pre-trained death state discrimination model, and outputting a death probability; and calculating a killing efficiency index based on the death probability evolution curve, and judging the activity level of the NK cells. The system comprises a phase image acquisition unit, a cell segmentation unit, a feature extraction unit, a death judgment unit and an activity judgment unit. Through unmarked imaging and deep learning fusion analysis, high-precision, real-time, quantitative and ultra-early NK cell activity evaluation is realized, and the method is suitable for clinical instant inspection and immunotherapy monitoring.

Provided for herein in several embodiments are immune cell-based (e.g., natural killer (NK) cell) compositions comprising CD19-directed chimeric antigen receptors. In some, embodiments the anti-CD19 binder portion of the CAR is humanized. In several embodiments, the humanized anti-CD19 CAR expressing cells exhibit enhanced expression of the CAR as well as enhanced cytotoxicity and / or persistence. Several embodiments include methods of using of the anti-CD19 CAR expressing immune cells in immunotherapy.

The invention discloses an MUC1-CAR-T cell for co-expressing a BTLA / IL-18R chimeric receptor as well as a preparation method and application of the MUC1-CAR-T cell, and belongs to the technical field of biological medicines. The MUC1-CAR-T cell comprises a BTLA / IL-18R chimeric receptor and an MUC1-CAR structure, wherein the BTLA / IL-18R chimeric receptor is a BTLA MUC1 is used as a targeting molecule for CAR-T cell therapy, an extracellular domain of BTLA is connected with a transmembrane domain and an intracellular domain of an IL-18 receptor, and the co-expression BTLA / IL-18R chimeric receptor is designed. Experimental verification shows that the BTLA / IL-18R chimeric receptor can significantly improve the tumor killing ability of MUC1-CAR-T cells, can better inhibit the growth of tumors, and provides a novel immunotherapy strategy for the treatment of pancreatic cancer.